Iga Nephropathy Pipeline and Clinical Trials Assessment (2023) | Companies- Aravive, Aduro BioTech, Alnylam Pharmaceuticals, Chinook Therapeutics, Transcenta Holding, Novartis Pharmaceuticals, Ionis Pharmaceuticals, Merck Serono, ZymoGenetics, and others.

DelveInsight's, "IgA Nephropathy Pipeline Insight, 2023," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the IgA Nephropathy pipeline landscape. It covers the IgA Nephropathy pipeline drug profiles, including IgA Nephropathy clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For IgA Nephropathy Emerging drugs, the IgA Nephropathy pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The IgA Nephropathy pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

In the IgA Nephropathy Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, IgA Nephropathy clinical trials studies, IgA Nephropathy NDA approvals (if any), and product development activities comprising the technology, IgA Nephropathy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

To explore more information on the latest breakthroughs in the IgA Nephropathy Pipeline treatment landscape of the report, click here @ IgA Nephropathy Pipeline Outlook- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key takeaways from the IgA Nephropathy Pipeline Report
• DelveInsight's IgA Nephropathy Pipeline analysis depicts a robust space with 30+ active players working to develop 30+ pipeline treatment therapies.
• The leading IgA Nephropathy Companies include Aravive, Aduro BioTech, Alnylam Pharmaceuticals, Chinook Therapeutics, Transcenta Holding, Novartis Pharmaceuticals, Ionis Pharmaceuticals, Merck Serono, ZymoGenetics, and others.
• Promising IgA Nephropathy Pipeline Therapies include Omega-3 fatty acid ethylester90, Budesonide, Tacrolimus, BION-1301, NEFECON, Blisibimod, RC18 160mg, LNP023, and others.
• The IgA Nephropathy companies and academics are working to assess challenges and seek opportunities that could influence IgA Nephropathy R&D. The IgA Nephropathy pipeline therapies under development are focused on novel approaches to treat/improve IgA Nephropathy.
• On November 7, 2022, Ionis Pharmaceuticals, Inc. presented positive results from a Phase 2 clinical study of IONIS-FB-LRx in patients with immunoglobulin A nephropathy (IgAN). Results from the study were presented in a poster session at the American Society of Nephrology's (ASN) Kidney Week 2022.
• On November 05, 2022, Vera Therapeutics, Inc. announced new clinical data presented on the Company's two product candidates, atacicept in immunoglobulin A nephropathy (IgAN) and MAU868 in kidney transplant. These data were presented in poster and oral presentations, respectively, at the American Society of Nephrology (ASN) Kidney Week 2022 Annual Meeting, held November 3-6, 2022, in Orlando, Florida.
• In October 2022, Transcenta Holding Limited announced that TST004, its best-in-class, humanized monoclonal antibody targeting MASP2, had received IND clearance from the U.S. Food and Drug Administration (FDA). MASP2, mannose-binding protein-associated serine protease 2, is a key enzyme in the lectin pathway initiation of complement activation. Studies have shown that lectin pathway activation contributes to multiple human diseases such as immunoglobulin A nephropathy (IgAN), hematopoietic stem-cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). Therefore, inhibition of MASP2 might be a potential treatment approach for diseases related to lectin pathway activation.
• In September 2022, Eledon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had cleared the company's Investigational New Drug (IND) application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN).

IgA Nephropathy Overview
IgA nephropathy, also known as Berger's disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody-a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. It is not known what causes IgA deposits in the glomeruli.

For further information, refer to the detailed IgA Nephropathy Unmet Needs, IgA Nephropathy Market Drivers, and IgA Nephropathy Market Barriers, click here for IgA Nephropathy Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

IgA Nephropathy Emerging Drugs Profile
• Atrasentan: Chinook Therapeutics
• Sparsentan: Travere Therapeutics

IgA Nephropathy Pipeline Therapeutics Assessment
There are approx. 30+ key companies which are developing the therapies for IgA Nephropathy. The companies which have their IgA Nephropathy drug candidates in the most advanced stage, i.e. Preregistration include, Travere Therapeutics.

Request a sample and discover the recent advances in IgA Nephropathy Ongoing Clinical Trial Analysis and Medications, click here @ IgA Nephropathy Treatment Landscape- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the IgA Nephropathy Pipeline Report
• Coverage- Global
• IgA Nephropathy Companies- Aravive, Aduro BioTech, Alnylam Pharmaceuticals, Chinook Therapeutics, Transcenta Holding, Novartis Pharmaceuticals, Ionis Pharmaceuticals, Merck Serono, ZymoGenetics, and others.
• IgA Nephropathy Pipeline Therapies- Omega-3 fatty acid ethylester90, Budesonide, Tacrolimus, BION-1301, NEFECON, Blisibimod, RC18 160mg, LNP023, and others
• IgA Nephropathy Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on IgA Nephropathy Mergers and acquisitions, IgA Nephropathy Licensing Activities @ IgA Nephropathy Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. IgA Nephropathy Executive Summary
3. IgA Nephropathy: Overview
4. IgA Nephropathy Pipeline Therapeutics
5. IgA Nephropathy Therapeutic Assessment
6. Late Stage Products (Pregistration)
7. Sparsentan: Travere Therapeutics
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Drug Name: Company Name
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. Drug Name: Company Name
14. Drug profiles in the detailed report…..
15. Inactive Products
16. IgA Nephropathy Key Companies
17. IgA Nephropathy Key Products
18. IgA Nephropathy- Unmet Needs
19. IgA Nephropathy- Market Drivers and Barriers
20. IgA Nephropathy- Future Perspectives and Conclusion
21. IgA Nephropathy Analyst Views
22. IgA Nephropathy Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.